Sameem M. Abedin, MD
2 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| MCW Master Predict (Profile Related Evidence Determining Individualized Cancer Therapy) (NCT05802069) | Sameem M. Abedin, MD | 2022-12-19 |
| Neihulizumab for Standard-Risk Acute Graft Versus Host Disease (GVHD) (NCT04144036) | Sameem M. Abedin, MD | 2020-12-14 |
Track Sameem M. Abedin, MD automatically
Every clearance here is in the API, with alerts when new ones post.